This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It
2026-07-17 12:30
•Leo Sun •The Motley Fool
••• •• Axe Capital view
Why SA Investors Should Watch Revolutionary Biotech RVMD
RVMD has soared 125% in 2026 on breakthrough cancer treatment hopes, but South African investors should tread carefully.
Revolution Medicines (RVMD) is making waves with its targeted cancer drug Daraxonrasib, which could replace traditional chemo. Its near-approval by the FDA and breakthrough designations explain the 125% jump this year and billionaire Stanley Druckenmiller's big bet. But this is still a pre-revenue biotech, meaning no current sales and heavy dependence on trial results and regulatory decisions. For JSE investors, RVMD isn't a direct play but the company's progress is positive news for global biotech sentiment, which can influence local pharma and healthcare stocks. However, the rand’s recent strength against the dollar (USD/ZAR) might offset gains for investors holding US-listed counters like RVMD. If regulatory hurdles come up or trials falter, the price can fall sharply. this is just my opinion and not financial advice
I’d watch RVMD closely but not buy here—too speculative without earnings. For local exposure, consider trimming pharma-related stocks if USD/ZAR weakens, as their costs can rise. Stay cautious until clearer earnings emerge.
- RVMD
- USD/ZAR
- Regulatory approval delays or failure
- Rand volatility impacting returns in USD-listed biotech
5/10
Revolution Medicines, a pre-revenue biotech company developing targeted cancer treatments to replace chemotherapy, has surged 125% in 2026. The company's flagship drug Daraxonrasib received FDA Breakthrough Therapy designation and is undergoing accelerated review by the EMA. Billionaire Stanley Druckenmiller's Duquesne Family Office purchased 316,000 shares worth $30.6 million in Q1 2026, now valued at $56.6 million, signaling confidence in the company's potential despite its speculative nature.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Leo Sun
Categories: Equities, Earnings, Healthcare
Tickers: RVMD, RVMDW
Sentiment: Positive - The company has achieved significant stock appreciation (125% YTD), received FDA Breakthrough Therapy and Orphan Drug designations, is nearing NDA completion, and has attracted high-profile billionaire investor Stanley Druckenmiller. The drug shows promising Phase 3 trial results with nearly doubled survival rates for pancreatic cancer patients, positioning it for potential global launch.
Keywords: biotech, cancer treatment, RAS protein, FDA approval, Daraxonrasib, pre-revenue company, institutional investment
Insights:
- RVMD: Positive: The company has achieved significant stock appreciation (125% YTD), received FDA Breakthrough Therapy and Orphan Drug designations, is nearing NDA completion, and has attracted high-profile billionaire investor Stanley Druckenmiller. The drug shows promising Phase 3 trial results with nearly doubled survival rates for pancreatic cancer patients, positioning it for potential global launch.
- RVMDW: Positive: The company has achieved significant stock appreciation (125% YTD), received FDA Breakthrough Therapy and Orphan Drug designations, is nearing NDA completion, and has attracted high-profile billionaire investor Stanley Druckenmiller. The drug shows promising Phase 3 trial results with nearly doubled survival rates for pancreatic cancer patients, positioning it for potential global launch.
Related coverage
- Sandisk Stock Has Jumped Over 500% in 2026. It Can Still Become a Multibagger Thanks to This Massive News
- Greg Abel Sees AI-Powered Growth Ahead for This Berkshire Hathaway Subsidiary. Can This Catalyst Help the Conglomerate Outperform in the AI Era?
- 2 Nuclear Stocks Poised to Benefit From Rising AI Adoption